Oncology

CHMP opines positively for 13 Drugs for a variety of disease The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the use of 13 medicinal drugs for a variety of indications. These include five new medications and eight existing ones whose use is extended to treat new indications. The new drugs to get approval include Epidyolex developed by GW Pharmaceuticals, Acorda Therapeutics’ Inbrija, Bayer’s Vitrakvi, Trogarzo of Theratechnologies and Mylan’s Deferasirox.  The other approved for expanding the indications are Tecentriq, Keytruda, E. mpliciti, Stelara, Lonsurf, Soliris, Zerbaxa and Lucentis. Bayer’s Vitra...